trial
as of 2026-07-01An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With Schizophrenia
NCTId NCT06924255
at a glance
Phase 4 · Not Yet Recruiting
Enrollment 100 (estimated)
Sponsored by Collaborative Neuroscience Research, LLC
Primary completion 2025-12
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Not Yet Recruiting
Enrollment
100 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2025-04
Primary completion
2025-12
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Collaborative Neuroscience Research, LLCLead Sponsor
Bristol-MyersCollaborator
Sites
7 total
Bellflower, United StatesGarden Grove, United StatesRiverside, United StatesTorrance, United StatesHollywood, United StatesGaithersburg, United StatesMarlton, United States
Facts & assertions
4 sourced
Enrollment
100
Phase
PHASE4
Primary Completion Date
2025-12
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
lead_sponsor
collaborator
company
indication
indication
indication